Please login to the form below
Adrenal insufficiency
This page shows the latest Adrenal insufficiency news and features for those working in and with pharma, biotech and healthcare.
Diurnal files adrenal insufficiency drug Alkindi in US
Could become only treatment for children with the condition. UK specialty drugmaker Diurnal has filed its Alkindi Sprinkle replacement therapy for children with adrenal insufficiency in the US, a group with ... There are estimated to be approximately 4,
Latest news
-
Aspen to pay millions to NHS following drug pricing investigation
According to the CMA, thousands of patients rely on the medicine, which is used to treat primary or secondary adrenal insufficiency (Addison’s Disease).
-
Resurgent Diurnal raises £5.4m for twin product filings
US filing for Alkindi as a replacement therapy for adrenal insufficiency. ... CAH is a potentially life-threatening orphan condition caused by a block in cortisol production, an essential adrenal steroid hormone.
-
Oncology bias in pharma deals
DuoCort's product, Plenadren, approved in the EU on November 3, is a once daily, dual-release oral glucocorticoid tablet for the treatment of adrenal insufficiency. ... Once daily, dual-release oral. glucocorticoid for adrenal insufficiency. 165. Onyx
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
